MYND Life Sciences Inc.
MYND
CNSX
| 07/31/2024 | 04/30/2024 | 01/31/2024 | 10/31/2023 | 07/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 244.00K | 240.40K | 235.30K | 247.00K | 236.20K |
| Gross Profit | -244.00K | -240.40K | -235.30K | -247.00K | -236.20K |
| SG&A Expenses | 454.60K | 443.70K | 634.90K | 884.30K | 891.60K |
| Depreciation & Amortization | 1.80K | 2.40K | 7.70K | 15.60K | 23.60K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 946.40K | 932.50K | 1.12M | 1.36M | 1.45M |
| Operating Income | -946.40K | -932.50K | -1.12M | -1.36M | -1.45M |
| Income Before Tax | -399.00K | -519.90K | -784.60K | -1.13M | -1.99M |
| Income Tax Expenses | -- | -- | -- | -- | -97.60K |
| Earnings from Continuing Operations | -0.40 | -0.52 | -0.78 | -1.13 | -1.89 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -399.00K | -519.90K | -784.60K | -1.13M | -1.89M |
| EBIT | -946.40K | -932.50K | -1.12M | -1.36M | -1.45M |
| EBITDA | -944.80K | -930.30K | -1.12M | -1.35M | -1.45M |
| EPS Basic | -0.01 | -0.01 | -0.02 | -0.02 | -0.04 |
| Normalized Basic EPS | -0.01 | -0.02 | -0.02 | -0.02 | -0.03 |
| EPS Diluted | -0.01 | -0.01 | -0.02 | -0.02 | -0.04 |
| Normalized Diluted EPS | -0.01 | -0.02 | -0.02 | -0.02 | -0.03 |
| Average Basic Shares Outstanding | 187.53M | 188.30M | 188.30M | 187.29M | 186.70M |
| Average Diluted Shares Outstanding | 187.53M | 188.30M | 188.30M | 187.29M | 186.70M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |